Literature DB >> 9314042

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

H Yokoshiki1, Y Katsube, M Sunagawa, N Sperelakis.   

Abstract

The electrophysiological effect of levosimendan, a novel Ca(2+)-sensitizing positive inotropic agent and vasodilator, was examined on rat mesenteric arterial myocytes using the patch clamp technique. Resting potential was significantly hyperpolarized with levosimendan, with an EC50 of 2.9 microM and maximal effect (19.5 +/- 3.5 mV; n = 12) at 10 microM. Levosimendan (10 microM) significantly increased the whole-cell outward current. The currents intersected close to the calculated EK (-84 mV), suggesting that the activated current was a K+ current. Hyperpolarization and stimulation of K+ current by levosimendan were not prevented by 30 microM H-7 (a non-specific inhibitor of protein kinases) and 100 nM charybdotoxin (a blocker of Ca(2+)-activated K+ channels), but were abolished by 10 microM glibenclamide. In single-channel current recording in open cell-attached patches, two types of K+ channels were observed having conductances of 26 and 154 pS. The 154 pS channels were not affected by levosimendan and glibenclamide. The 26 pS channels were evoked in one-fourth of the patches when 10 microM levosimendan (and 0.1 mM UDP) was added (at -60 mV) and channel activity was abolished by glibenclamide. The mean open probability of the 26 pS channels was 0.094 +/- 0.017 (n = 9), and the mean open time (at -60 mV) was 6.6 ms in the presence of UDP and levosimendan. Although significant hyperpolarization (4.7 +/- 1.5 mV, n = 8) was observed at 1 microM levosimendan, the same concentration did not affect Ca2+ channel currents (n = 10). In summary, levosimendan hyperpolarized the arterial myocytes, probably through activation of a glibenclamide-sensitive K+ channel. This mechanism may contribute to the vasodilating action of levosimendan.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314042     DOI: 10.1016/s0014-2999(97)01108-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  47 in total

1.  Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock.

Authors:  Muhuo Ji; Renqi Li; Guo-min Li; Yunxia Fan; Lin Dong; Jianjun Yang; Yong G Peng; Jing Wu
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.

Authors:  Nóra Erdei; Zoltán Papp; Piero Pollesello; István Edes; Zsolt Bagi
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

3.  Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study.

Authors:  Arnaldo Dubin; Gastón Murias; Juan Pablo Sottile; Mario Omar Pozo; Marcelo Barán; Vanina Siham Kanoore Edul; Héctor Saúl Canales; Graciela Etcheverry; Bernardo Maskin; Elisa Estenssoro
Journal:  Intensive Care Med       Date:  2007-01-30       Impact factor: 17.440

4.  Levosimendan restores the positive force-frequency relation in heart failure.

Authors:  Satoshi Masutani; Heng-Jie Cheng; Hideo Tachibana; William C Little; Che-Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

Review 5.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

6.  Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model.

Authors:  E du Toit; D Hofmann; J McCarthy; C Pineda
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

7.  Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery.

Authors:  K Distelmaier; C Roth; L Schrutka; C Binder; B Steinlechner; G Heinz; I M Lang; G Maurer; H Koinig; A Niessner; M Hülsmann; W Speidl; G Goliasch
Journal:  Br J Anaesth       Date:  2016-07       Impact factor: 9.166

8.  Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery.

Authors:  Abdelhay A Ebade; Mohamed A Khalil; Ahmed K Mohamed
Journal:  J Anesth       Date:  2012-12-09       Impact factor: 2.078

9.  Effect of levosimendan in experimental verapamil-induced myocardial depression.

Authors:  Jouni Kurola; Heli Leppikangas; Jarkko Magga; Leena Lindgren; Vesa Kiviniemi; Juha Rutanen; Esko Ruokonen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-03-11       Impact factor: 2.953

10.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.